News/ News/ News/ R&D/ Sales and Marketing GSK bolsters vaccines division with $3.3bn swoop on Affinivax Phil Taylor Affinivax, GlaxoSmithKline, M&A, pneumococcal disease, vaccine 0 Comment GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is Share X GSK bolsters vaccines division with $3.3bn swoop on Affinivax https://pharmaphorum.com/news/gsk-bolsters-vaccines-division-with-3-3bn-swoop-on-affinivax/
News/ News/ R&D Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar Phil Taylor Affinivax, Astellas, Merck & Co, Pfizer, Prevnar 13, Prevnar 20, V114, vaccine 0 Comment Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Share X Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar https://pharmaphorum.com/news/shot-in-the-arm-for-affinivax-as-it-challenges-pfizers-prevnar/
Affinivax, GlaxoSmithKline, M&A, pneumococcal disease, vaccine
0 Comment
